Dupilumab Shows Promising Results for Hair Regrowth in Pediatric Alopecia Areata, with No New Safety Concerns: Study Medha Baranwal17 Aug 2024 9:30 AM ISTUSA: A real-world, single-center observational study revealed that dupilumab significantly enhanced hair regrowth in pediatric patients with alopecia...
Dupilumab effective in adults with moderate to severe atopic dermatitis: JAMA Jacinthlyn Sylvia19 July 2024 2:30 AM ISTA recent trial by Lisa Beck and team found that continued long-term dupilumab therapy was safe and effective for individuals with moderate to severe...
Dupixent approved in EU as targeted therapy for COPD: Sanofi, Regeneron Pharma Ruchika Sharma3 July 2024 2:00 PM ISTParis: Sanofi and Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has approved Dupixent (dupilumab) as...
Live vaccinations safe and effective among patients taking Dupilumab, reveals Study Jacinthlyn Sylvia27 Jun 2024 8:45 PM ISTThe new advancement published in the recent issue of the Annals of Allergy, Asthma & Immunology unveiled promising insights into the safety...
Upadacitinib Outperforms Dupilumab in Treating Atopic Dermatitis: Study Dr Riya Dave4 Jun 2024 8:00 PM ISTResearchers have found that upadacitinib (Rinvoq) was more effective than dupilumab (Dupixent) in treating moderate-to-severe atopic dermatitis in a...
USFDA requests additional data on Sanofi Dupixent for treating smoker's lung Ruchika Sharma31 May 2024 3:16 PM ISTParis: Sanofi and Regeneron have announced that the US Food and Drug Administration (FDA) requested additional efficacy analyses on the efficacy...
Dupilumab lowers exacerbations in COPD and type 2 inflammation and improves lung function: NEJM Dr. Kamal Kant Kohli25 May 2024 8:15 AM ISTChronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug-dupilumab-that showed rapid and sustained...
Dupilumab Linked to Increased Risk of Cutaneous T Cell Lymphoma in Atopic Dermatitis Patients: Study Dr Riya Dave23 April 2024 10:15 PM ISTResearchers have found that the use of dupilumab, a human monoclonal antibody targeting the IL-4 alpha receptor, is associated with an increased risk...
Dupilumab safe to continue during vaccine administration in children with AD reveals study Aditi20 March 2024 7:00 PM ISTDupilumab inhibits interleukin (IL)-4 and IL-13 signalling. This monoclonal antibody also acts as an immunomodulator. The current recommendation is to...
Dupilumab treatment may improve work productivity in patients with atopic dermatitis: Study Medha Baranwal19 March 2024 2:30 AM ISTJapan: A recent study published in Experimental Dermatology has shed light on the impact of 1-year treatment with dupilumab on work productivity in...
Tezepelumab novel therapeutic approach in uncontrolled severe non-type 2 asthma, case study suggests Medha Baranwal12 March 2024 3:00 AM ISTJapan: A recent case study published in Respirology Case Reports has shown that Tezepelumab could serve as a novel therapy for patients with...
Dupixent application accepted for priority review by USFDA for COPD with type 2 inflammation Ruchika Sharma23 Feb 2024 4:30 PM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License...
